Throwsters, The Street
15 articles with AMO Pharma
AMO Pharma Participates in Workshop on Central Nervous System Involvement in Progression and Treatment of Myotonic Dystrophy During Myotonic Dystrophy Foundation Annual Conference
AMO Pharma Limited ("AMO Pharma"), today announced that Joe Horrigan, MD, AMO Pharma's chief medical officer, presented an update on the company's research targeting use of CNS therapies in the treatment of myotonic dystrophy (DM) during a full-day workshop on CNS involvement in DM held during the Myotonic Dystrophy Foundation Annual Conference
AMO Pharma Presents Statistical Analysis of Results of Phase 2 Study of AMO-02 in Adolescents with Autism Spectrum Disorder
Results highlighting consistent patterns in efficacy across multiple outcomes measures presented at International Society for Autism Research Annual Meeting in Montreal.
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
AMO Pharma Announces Launch of First Clinician-Completed Rating Scale for Congenital Myotonic Dystrophy Type 1
Rating scale positioned to deliver meaningful benefit for clinical research presented at 2019 MDA Clinical and Scientific Conference in Orlando, FL
There are no treatments for autism, but that’s not stopping research into the development of therapies for core symptoms of autism spectrum disorder. This week, London-based AMO Pharma reported Phase II results from its investigational glycogen synthase kinase 3 (GSK3) beta inhibitor, AMO-02 (tid...
U.S. Food and Drug Administration has granted Orphan Drug Designation to its investigational therapy AMO-04 for the treatment of Rett syndrome, a rare childhood neurodevelopmental disorder.
AMO Pharma Announces Initiation of Clinical Trial conducted by Mount Sinai to Study AMO-01 in Treatment of Phelan-McDermid Syndrome
AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare, debilitating childhood onset neurogenetic disorders with limited or no treatment options, today announced initiation of patient recruitment in an interventional study of AMO-01, the company's investigational Ras-ERK pathway inhibitor, in the treatment of Phelan-McDermid syndrome.
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an increased ability to perform daily tasks.
AMO Pharma Presents Positive Interim Analysis of Data from Congenital Myotonic Dystrophy Study at American Neurological Association Annual Meeting
AMO Pharma presented positive interim analysis of data from the first cohort of its study of AMO-02 in congenital myotonic dystrophy.
AMO Pharma Reports Update On Positive Interim Analysis For The First Cohort Of Phase IIa Congenital Myotonic Dystrophy Study
AMO Pharma Receives FDA Orphan Drug Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
AMO Pharma Enters Into Development And License Agreement With Numedicus Limited For Rett Syndrome Program
AMO Pharma Announces FDA Fast Track Designation For AMO-02 For Treatment Of Congenital Myotonic Dystrophy
AMO Pharma Presents Pre-Clinical Data Showing AMO-01 Successfully Inhibits Activated Pathway Associated With Fragile X Syndrome